Skip to content

Rehabilitation for Patients With Pulmonary Arterial Hypertension

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00544726
Enrollment
45
Registered
2007-10-16
Start date
2008-02-29
Completion date
Unknown
Last updated
2008-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Keywords

Rehabilitation

Brief summary

Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life. In many other serious heart or lung diseases it has been shown that physical rehabilitation improves patient's fitness and quality of life. In PAH there are no clear guidelines and in general physical activity has traditionally been discouraged, although evidence for this advice is lacking. Interesting research project in Germany showed significant benefit for in-patient rehabilitation in PAH patients. In this study we will perform a controlled clinical study of out-patient rehabilitation of patients with PAH. We hypothesize that physical training of patients will result in increased exercise capacity and improved quality of life.

Interventions

BEHAVIORALPhysical training
BEHAVIORALNo training

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients must satisfy current diagnostic criteria for pulmonary artery hypertension based on their historical right heart catheter data (within 4 years of study enrollment): Mean PAP \>25mmHg at rest or \>30mmHg with exercise, by a PCWP \<= 15mmHg and by PVR \>3 Wood Units. * Willing and able to participate in 24 bi-weekly rehabilitation sessions, and medical follow-up. * Stable dose of current PAH-specific medication for 3 months prior to enrollment. * New York Heart Association (NYHA) Class II-III. * Women of child-bearing age must demonstrate adequate contraception or undergo a pregnancy test.

Exclusion criteria

* Functional Class NYHA Class I or IV. * PAH due to congenital heart disease, left heart disease, chronic lung diseases (VC or FEV1 \< 60% of predicted) or chronic hypoxia. * Acute intercurrent illness requiring hospital admission in the month proceeding screening. * Any non-PAH medical condition likely to interfere with participation in rehabilitation, e.g. musculoskeletal disorders. * Any uncontrolled or terminal non-PAH medical condition likely to interfere with completion of the study, according to the judgment of the study physician. * Participation in another rehabilitation scheme within 6 months of enrollment in the study. * Current participation in another clinical trial. * Pregnancy or planned pregnancy during the study period.

Design outcomes

Primary

MeasureTime frame
Six minute walking distance3 months
New York Heart Association (NYHA) functional class3 months

Secondary

MeasureTime frame
Echocardiographic parameters3 months
Quality of life as assessed by the SF-363 months
Performance in cardiopulmonary exercise test3 months

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026